| Active substance | durvalumab |
| Holder | Astra Zeneca S.A./N.V. |
| Status | Running |
| Indication | Imfinzi® (durvalumab) as monotherapy for the treatment of patients with limited stage small-cell lung cancer (LS-SCLC) who have not progressed following platinum-based chemoradiation therapy. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update |
31/10/2024 |